JP7854946B2 - 核酸人工ミニプロテオームライブラリー - Google Patents
核酸人工ミニプロテオームライブラリーInfo
- Publication number
- JP7854946B2 JP7854946B2 JP2022573214A JP2022573214A JP7854946B2 JP 7854946 B2 JP7854946 B2 JP 7854946B2 JP 2022573214 A JP2022573214 A JP 2022573214A JP 2022573214 A JP2022573214 A JP 2022573214A JP 7854946 B2 JP7854946 B2 JP 7854946B2
- Authority
- JP
- Japan
- Prior art keywords
- rna
- puromycin
- polypeptide
- tagged
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026070113A JP2026117232A (ja) | 2020-05-26 | 2026-04-21 | 核酸人工ミニプロテオームライブラリー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063030056P | 2020-05-26 | 2020-05-26 | |
| US63/030,056 | 2020-05-26 | ||
| PCT/US2021/034131 WO2021242793A2 (en) | 2020-05-26 | 2021-05-26 | Nucleic acid artificial mini-proteome libraries |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026070113A Division JP2026117232A (ja) | 2020-05-26 | 2026-04-21 | 核酸人工ミニプロテオームライブラリー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023528805A JP2023528805A (ja) | 2023-07-06 |
| JP2023528805A5 JP2023528805A5 (cg-RX-API-DMAC10.html) | 2024-06-04 |
| JP7854946B2 true JP7854946B2 (ja) | 2026-05-07 |
Family
ID=76859704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573214A Active JP7854946B2 (ja) | 2020-05-26 | 2021-05-26 | 核酸人工ミニプロテオームライブラリー |
| JP2026070113A Pending JP2026117232A (ja) | 2020-05-26 | 2026-04-21 | 核酸人工ミニプロテオームライブラリー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026070113A Pending JP2026117232A (ja) | 2020-05-26 | 2026-04-21 | 核酸人工ミニプロテオームライブラリー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230203477A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4158014A2 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7854946B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230029673A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116249774A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021280261A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3185387A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021242793A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023034901A1 (en) | 2021-09-01 | 2023-03-09 | The Broad Institute, Inc. | Tumor avatar vaccine compositions and uses thereof |
| US12112833B2 (en) | 2020-02-04 | 2024-10-08 | 10X Genomics, Inc. | Systems and methods for index hopping filtering |
| US12168801B1 (en) * | 2020-07-02 | 2024-12-17 | 10X Genomics, Inc. | Hybrid/capture probe designs for full-length cDNA |
| US12580044B1 (en) | 2020-09-02 | 2026-03-17 | 10X Genomics, Inc. | Systems and methods for identifying cells that are antigen-specific for an immunogenic feature |
| US20250144198A1 (en) * | 2021-08-16 | 2025-05-08 | Duke University | Next generation vaccines comprising antigenic libraries and methods of making and using same |
| WO2023076733A1 (en) * | 2021-11-01 | 2023-05-04 | Dana-Farber Cancer Institute, Inc. | Biologically selected nucleic acid artificial mini-proteome libraries |
| EP4594488A1 (en) * | 2022-09-29 | 2025-08-06 | Twist Bioscience Corporation | Libraries for rna enrichment |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522091A (ja) | 1998-08-17 | 2002-07-23 | フィロス インク. | 3’非翻訳領域を欠損する核酸を生成して細胞rna蛋白質融合体形成を最適化する方法 |
| WO2005035751A1 (ja) | 2003-10-15 | 2005-04-21 | Keio University | 高機能性タンパク質の迅速、高効率な選択法、それによって得られる高機能性タンパク質、およびその製造方法と利用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| US4226859A (en) | 1979-06-07 | 1980-10-07 | Velsicol Chemical Corporation | Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| EP0575491B1 (en) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US6991797B2 (en) | 1993-07-02 | 2006-01-31 | Statens Serum Institut | M. tuberculosis antigens |
| ES2243937T3 (es) | 1994-04-29 | 2005-12-01 | Baxter Healthcare S.A. | Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños. |
| US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
| US7255862B1 (en) | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
| WO1999014354A1 (en) | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| WO2000006717A2 (en) | 1998-07-27 | 2000-02-10 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
| EP1101490B1 (en) | 1998-07-28 | 2005-04-13 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
| US6955808B2 (en) | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| ES2376454T3 (es) | 2000-12-22 | 2012-03-14 | Grad, Carole, Legal Representative Of Howard, Kaplan | Librer�?as de expresión en fago de fragmentos vh humanos. |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| EP2397490B1 (en) | 2004-07-16 | 2013-09-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV |
| EP2573185A3 (en) | 2005-02-16 | 2013-06-05 | Lentigen Corporation | Lentiviral vectors and their use |
| JP2011512326A (ja) | 2007-12-31 | 2011-04-21 | ナノコア セラピューティクス,インコーポレイテッド | 心不全の治療用のrna干渉 |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| LT2714071T (lt) | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| WO2018213803A1 (en) * | 2017-05-19 | 2018-11-22 | Neon Therapeutics, Inc. | Immunogenic neoantigen identification |
| WO2020018461A1 (en) * | 2018-07-16 | 2020-01-23 | The University Of Virginia Patent Foundation | Compositions and methods of diagnosis and treatment for neurological diseases |
-
2021
- 2021-05-26 JP JP2022573214A patent/JP7854946B2/ja active Active
- 2021-05-26 EP EP21740278.3A patent/EP4158014A2/en active Pending
- 2021-05-26 KR KR1020227045521A patent/KR20230029673A/ko active Pending
- 2021-05-26 AU AU2021280261A patent/AU2021280261A1/en active Pending
- 2021-05-26 WO PCT/US2021/034131 patent/WO2021242793A2/en not_active Ceased
- 2021-05-26 CA CA3185387A patent/CA3185387A1/en active Pending
- 2021-05-26 US US17/927,112 patent/US20230203477A1/en active Pending
- 2021-05-26 CN CN202180048206.XA patent/CN116249774A/zh active Pending
-
2026
- 2026-04-21 JP JP2026070113A patent/JP2026117232A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522091A (ja) | 1998-08-17 | 2002-07-23 | フィロス インク. | 3’非翻訳領域を欠損する核酸を生成して細胞rna蛋白質融合体形成を最適化する方法 |
| WO2005035751A1 (ja) | 2003-10-15 | 2005-04-21 | Keio University | 高機能性タンパク質の迅速、高効率な選択法、それによって得られる高機能性タンパク質、およびその製造方法と利用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230029673A (ko) | 2023-03-03 |
| EP4158014A2 (en) | 2023-04-05 |
| CN116249774A (zh) | 2023-06-09 |
| JP2026117232A (ja) | 2026-07-14 |
| US20230203477A1 (en) | 2023-06-29 |
| WO2021242793A2 (en) | 2021-12-02 |
| WO2021242793A3 (en) | 2022-02-24 |
| JP2023528805A (ja) | 2023-07-06 |
| AU2021280261A1 (en) | 2023-01-19 |
| CA3185387A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230203477A1 (en) | Nucleic acid artificial mini-proteome libraries | |
| JP5016614B2 (ja) | キメラアデノウイルスベクター | |
| CN111492056B (zh) | 用于细胞的遗传修饰的非整合型dna载体 | |
| JP7034080B2 (ja) | ヒトflt3lを発現する組換えmvaまたはmvaδe3lおよび固形腫瘍に対する免疫療法薬としてのそれらの使用 | |
| US12247214B2 (en) | Vaccinia viral vectors encoding chimeric virus like particles | |
| KR20160030317A (ko) | 유전자 조작된 항체 유전자 발현 카세트를 갖는 미니서클 dna 재조합 모 플라스미드, 상기 발현 카세트를 갖는 미니서클 dna 및 용도 | |
| CN110923255B (zh) | 靶向bcma和cd19嵌合抗原受体及其用途 | |
| CN105246496A (zh) | 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体 | |
| AU2016205208A1 (en) | Methods and compositions for ebola virus vaccination | |
| CN111349645A (zh) | 一种提高非整合减毒李斯特菌疫苗安全性的方法 | |
| CN115989321B (zh) | 病毒制剂、用于配制病毒制剂的溶液及其用途 | |
| CN116199787A (zh) | 一种基于uPA的GFD结构域构建的嵌合抗原受体免疫细胞制备及其应用 | |
| CN105585637B (zh) | 基于il-12稳定膜表达的肿瘤治疗剂及其制法和用途 | |
| CN117004579B (zh) | 重组溶瘤牛痘病毒及其应用 | |
| WO2023076733A1 (en) | Biologically selected nucleic acid artificial mini-proteome libraries | |
| WO2024026274A2 (en) | Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc) | |
| WO2023217192A1 (zh) | 基于msln前体蛋白构建的嵌合抗原受体免疫细胞制备及其应用 | |
| WO2017117890A1 (zh) | Il-12/cd107a融合蛋白及其制法和用途 | |
| CN115819614A (zh) | 一种基于il34的嵌合抗原受体免疫细胞制备及其应用 | |
| JP2025534300A (ja) | Ctaワクチンカセット | |
| CN121873266A (zh) | 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途 | |
| WO2004050112A1 (en) | Intratumor administration of heat shock protein and its combination tumor therapy with cell toxin | |
| HK1226097B (en) | Rna transcription vector and uses thereof | |
| CN104491852A (zh) | 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗 | |
| MXPA02003986A (en) | Chimeric immunogenic compositions and nucleic acids encoding them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240527 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240527 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250418 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250530 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250901 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260323 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260421 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7854946 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |